Business
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
VENLO, the Netherlands, April 29, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy.
About this update from Qiagen N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":242,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/2c47efe3eb3511b295797dff5d0e8e60"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jyTvuOiYDEaR6T77yFKQGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2c47efe3eb3511b295797dff5d0e8e60","width":242,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"QIAcuity digital PCR kits, assays and protocols for lentivirus-based therapies support quality control in cell and gene therapy manufacturing","length":141,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":141,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expansion underscores the commitment of QIAGEN to help accelerate the development of safe and effective biotherapeutics","length":119,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":119,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"New solutions support high-precision analytics for process development, batch release and regulatory compliance and enable a standardized workflow","length":146,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":146,"olType":false},{"type":"text","content":"VENLO, the Netherlands, April 29, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy.","length":440,"tagName":"p"},{"type":"text","content":"This expanded offering supports standardized, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organizations (CDMO) and therapy developers in CGT manufacturing.","length":321,"tagName":"p"},{"type":"text","content":""Cell and gene therapy developers face increasing demands for precise, scala...